Brez internetne povezave — prikazana je shranjena različica strani.

Amgen Inc

USUSD
← Na filter delnic

Amgen Inc (US:AMGN) — Biotechnology: Biological Products (No Diagnostic Substances). Število borz, na katerih se trgujejo delnice družbe: 4. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O podjetju

Spletna stran
amgen.com
Odnosi z vlagatelji
investors.amgen.com/
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sedež
Thousand Oaks, United States
Izvršni direktor
Mr. Robert A. Bradway
Zaposleni
17 900
Ustanovljena
1980
Delnice v obtoku
540.63 mio. na dan 2026-07-30
Prosto prenosljive delnice
539.16 mio.
Tržna kapitalizacija
226.05 mrd. USD
Notranje osebe
0.23%
Institucionalni vlagatelji
85.02%
Panoga (SIC)
Biological Products, (No Diagnostic Substances)
Pravna oblika
XTIQ
ISIN
US0311621009
LEI
62QBXGPJ34PQ72Z12S66
Delež izplačila
60.4%
FCF
10.2 mrd. USD
52%
Dolg
57.3 mrd. USD
4.3 let FCF
Dividendni staž
15 let
Dobički, FCF in izplačane dividende — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
Opis

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Borze in oznake

BorzaOznakaValutaCenaVrsta
US USA StocksAMGN glavnaUSD407.44 -1.37%navadne delnice
LSE London Stock Exchange0R0T IOBUSD411.854 +1.17%navadne delnice
MX Mexican Stock ExchangeAMGN dodatnaMXN7 500.0098 +0.00%navadne delnice
XETRA XetraAMG dodatnaEUR367.95 -1.39%navadne delnice

Cena v 3 mesecih

dan rasti dan padca ex-dividendni datum datum izplačilaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Dividende

Zadnjih 12 mesecev, US:AMGN: 9.94 USD (4 izpl.)

Amgen Inc (AMGN) izplačuje dividende četrtletno. V zadnjih 12 mesecih je bilo plačanih 9.94 USD na delnico (plačila: 4). To je približno 2.44% trenutne cene delnice. Glede na zgodovino izplačil se naslednji datum ex-dividende pričakuje okoli 20.11.2026. Leta neprekinjenih dividend: 15.

Ex-datumIzplačiloZnesek%VrstaOznaka
2026-08-212026-09-112.5200 USD0.6/2.4 %četrtletnoUS:AMGN
2026-05-152026-06-052.5200 USD0.6/2.4 %četrtletnoUS:AMGN
2026-02-132026-03-062.5200 USD0.6/2.4 %četrtletnoUS:AMGN
2025-11-212025-12-122.3800 USD0.6/≈2.3 %četrtletnoUS:AMGN
2025-08-222025-09-122.3800 USD0.6/≈2.3 %četrtletnoUS:AMGN
2025-05-162025-06-062.3800 USD0.6/≈2.3 %četrtletnoUS:AMGN

Novice ta teden

Novic s spletnega mesta podjetja še ni.

oglas

Največji imetniki

ImetnikDeležDelniceDatum poročila
Blackrock Inc.9.13%49.36 mio.2026-06-30
Vanguard Capital Managem…6.52%35.25 mio.2026-06-30
State Street Corporation5.65%30.56 mio.2026-06-30
Capital World Investors5.38%29.08 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%17.13 mio.2026-06-30
Invesco Ltd.3.02%16.32 mio.2026-06-30
Geode Capital Management…2.9%15.7 mio.2026-06-30
Charles Schwab Investmen…2.78%15.03 mio.2026-06-30
Vanguard Portfolio Manag…2.75%14.85 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%13.99 mio.2026-06-30
Morgan Stanley2.53%13.65 mio.2026-06-30
Invesco QQQ Trust, Serie…2.15%11.61 mio.2026-08-31
SCHWAB STRATEGIC TRUST-S…1.81%9.79 mio.2026-05-31
Income Fund of America1.44%7.76 mio.2026-06-30
iShares Trust-iShares Co…1.35%7.28 mio.2026-07-31
Wells Fargo & Company1.34%7.24 mio.2026-06-30
AMERICAN BALANCED FUND1.31%7.09 mio.2026-06-30
Fidelity Concord Street…1.29%6.98 mio.2026-07-31
SPDR S&P 500 ETF TRUST-S…1.22%6.6 mio.2026-08-31
WASHINGTON MUTUAL INVEST…1.16%6.27 mio.2026-06-30
BRADWAY ROBERT A (Chief…≈0.12%657 2992026-05-05
SANTOS ESTEBAN (Officer)≈0.02%84 2792026-05-05
GORDON MURDO (Officer)≈0.01%51 8372026-05-05
GRIFFITH PETER H. (Chief…≈0.01%50 7062026-05-05
REESE DAVID M. (Chief Te…≈0.01%42 8122026-05-05
GRAHAM JONATHAN P (Gener…≈0.01%40 2112026-05-05
BRADNER JAMES E. (Office…≈0.01%30 4622026-05-05
ECKERT ROBERT ANDREW (Di…≈0%26 2512026-05-19
JACKS TYLER (Director)≈0%18 2842026-05-19
KULLMAN ELLEN JAMISON (D…≈0%14 5362026-05-19